Page 9 of 56 Express Mail Tracking Number: EV 938 354 435 US

Attorney Docket No.: EX04-017C-US USSN: 10/565,657

In the Claims

Claims 1-30 are pending in this Application.

Original Claims 1-30 are canceled.

Claims 31-58 are new.

31. (new) A compound according to formula I,

or a pharmaceutically acceptable salt or a stereoisomer, thereof, wherein,

A is a five- to ten-membered ring containing up to three heteroatoms; provided A is not a saturated alicyclic when X^2 is =N-, X^3 is -O-, and A is a pyridin-4-yl;

 R^1 is selected from -H, halo, trihalomethyl, -CN, -NO₂, -OR⁴, -N(R⁴)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -C(=O)N(R⁴)R⁴, -C(=O)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, alkoxy, C₁₋₆ alkyl, aryl, aryl C₁₋₆ alkyl, heterocyclyl, and heterocyclyl C₁₋₆ alkyl;

two adjacent of R^1 , together with the annular atoms to which they are attached, can form a five- to six-membered ring containing up to two heteroatoms and optionally substituted with up to four of R^{10} ;

R² and R³, together with the annular atoms to which they are attached, form a five- to six-membered ring containing up to two heteroatoms and optionally substituted with up to five of R⁶;

each R⁴ is selected from -H; C₁₋₆ alkyl optionally substituted with 1, 2, or 3 halogen; C₁₋₆ alkyl optionally substituted with alkoxy; C₁₋₆ alkyl substituted with amino where the amino is optionally substituted with one or groups selected from methyl, ethyl, -CH₂CH₂OCH₃, -CH₂CH₂N(CH₃)₂, -CH₂CH₂CH₂N(CH₃)₂, and *N*-methyl-pyrrolidin3-yl; aryl; aryl C₁₋₆ alkyl; heterocyclyl; and heterocyclyl C₁₋₆ alkyl where the heterocyclyl is

Attorney Docket No.: EX04-017C-US

Page 10 of 56
USSN: 10/565,657

Express Mail Tracking Number: EV 938 354 435 US

optionally substituted with alkyl, acyl, NH₂, alkylamino, dialkylamino, heterocyclyl, cyclohexyl, -CH₂OCH₃, -CH₂C(O)NHCH(CH₃)₂, or -CH₂OCH₃;

two of R⁴, when taken together with a common nitrogen to which they are attached, form an five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;

each R^5 is selected from -H, -CN, -NO₂, -OR⁴, -S(O)₀₋₂R⁴, -CO₂R⁴, C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl;

Y is =N- or =
$$C(R^8)$$
-;

 X^1 and X^2 are each independently either =N- or =C(R^9)-;

 X^3 is selected from $-N(R^7)$ -, -O-, and -S-;

R⁷ is hydrogen;

each of R^6 , R^8 , and R^{10} is independently selected from -H, halo, trihalomethyl, -CN, -NO₂, -OR⁴, -N(R⁴)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -C(=O)R⁴, optionally substituted alkoxy, C_{1-6} alkyl, aryl, aryl C_{1-6} alkyl, heterocyclyl, and heterocyclyl C_{1-6} alkyl;

two adjacent of R⁶, together with the annular atoms to which they are attached, can form a five- to seven-membered ring containing up to two heteroatoms; and

each R^9 is independently selected from -H; halo; trihalomethyl; -CN; $-NO_2$; $-OR^4$; $-N(R^4)R^4$; $-S(O)_{0-2}R^4$; $-SO_2N(R^4)R^4$; $-CO_2R^4$; $-C(=O)N(R^4)R^4$; $-C(=NR^5)N(R^4)R^4$; $-C(=NR^5)R^4$; $-N(R^4)SO_2R^4$; $-N(R^4)C(O)R^4$; $-C(=O)R^4$; alkoxy; C_{1-6} alkyl optionally substituted with one group selected from alkoxy, benzylamino, and 2-oxo-pyrrolidinyl; aryl C_{1-6} alkyl substituted on the aryl with 1 or 2 groups selected from alkyl and alkoxy; heterocyclyl optionally substituted with -C(O)Ot-Bu; and heterocyclyl C_{1-6} alkyl; provided when R^9 is aryl, heteroaryl, -C(H)=C(H)R or -C(H)=NR, where R is an

Attorney Docket No.: EX04-017C-US

Page 11 of 56
USSN: 10/565,657

Express Mail Tracking Number: EV 938 354 435 US

optionally substituted alkyl, cycloalkyl, heteroalicyclic, aryl, or heteroaryl, then Y is not =C(H)-.

- 32. (new) The compound according to claim 31, wherein the five- to six-membered ring formed by R^2 and R^3 is an aryl or a heteroaryl optionally substituted with up to five of R^6 ; or a pharmaceutically acceptable salt or stereoisomer, thereof.
- 33. (new) The compound according to claim 32, wherein the five- to six-membered ring formed by R^2 and R^3 is phenyl or pyridyl optionally substituted with up to five of R^6 ; or a pharmaceutically acceptable salt or stereoisomer, thereof.
- 34. (new) The compound according to claim 33, of formula II,

or a pharmaceutically acceptable salt or stereoisomer, thereof.

- 35. (new) The compound according to claim 34, wherein X^1 is $=C(R^9)$ -, X^2 is =N-, X^3 is $-N(R^7)$ -, and R^7 is hydrogen; or a pharmaceutically acceptable salt or stereoisomer, thereof.
- 36. (new) The compound according to claim 35, wherein Y is =N-; or a pharmaceutically acceptable salt or stereoisomer, thereof.
- 37. (new) The compound according to claim 36, wherein A is either a six- to tenmembered aryl or a five- to ten-membered heteroaryl containing up to three heteroatoms; or a pharmaceutically acceptable salt or stereoisomer, thereof.
- 38. (new) The compound according to claim 37, wherein A is either a six-membered aryl or a five- or six-membered heteroaryl containing up to three heteroatoms; or a pharmaceutically acceptable salt or stereoisomer, thereof.

Attorney Docket No.: EX04-017C-US

Page 12 of 56
USSN: 10/565,657

Express Mail Tracking Number: EV 938 354 435 US

39. (new) The compound according to claim 38, wherein R^1 is selected from -H, halo, trihalomethyl, -CN, -OR⁴, -N(R⁴)R⁴, -SO₂N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, alkoxy, C_{1-6} alkyl, heterocyclyl, and heterocyclyl C_{1-6} alkyl; or a pharmaceutically acceptable salt or stereoisomer, thereof.

40. (new) The compound according to claim 39, of formula III,

wherein R⁷ is hydrogen and at least one of R¹ is -OH; or a pharmaceutically acceptable salt or stereoisomer, thereof.

41. (new) The compound according to claim 40, wherein the compound is either of Formula IIa or IIIb:

$$(R^{6})_{1-4}$$
 $(R^{6})_{1-4}$
 $(R^{6})_{1-4}$
 $(R^{1})_{1-4}$
 $(R^{1})_{1-4}$
 $(R^{1})_{1-4}$
 $(R^{1})_{1-4}$

or a pharmaceutically acceptable salt or stereoisomer, thereof.

42. **(new)** The compound according to claim 41, wherein R^9 is selected from –H; trihalomethyl; C_{1-6} alkyl optionally substituted with one group selected from alkoxy, benzylamino, and 2-oxo-pyrrolidinyl; aryl C_{1-6} alkyl substituted on the aryl with 1 or 2 groups selected from alkyl and alkoxy; heterocyclyl optionally substituted with -C(O)Ot-

Attorney Docket No.: EX04-017C-US

Page 13 of 56
USSN: 10/565,657

Express Mail Tracking Number: EV 938 354 435 US

Bu; and heterocyclyl C₁₋₆ alkyl; or a pharmaceutically acceptable salt or stereoisomer, thereof.

43. (new) The compound according to claim 42, wherein R^6 is selected from -H, halo, trihalomethyl, -CN, -OR⁴, -N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -C(=O)R⁴, C₁₋₆ alkyl, heterocyclyl, heterocyclyl C₁₋₆ alkyl, and a six- or seven-membered heteroalicyclic formed by two adjacent of R^6 , together with the annular atoms to which they are attached, said six- or seven-membered heteroalicyclic containing up to two heteroatoms; or a pharmaceutically acceptable salt or stereoisomer, thereof.

- 44. (new) The compound according to claim 43, wherein R^6 is selected from -H, halo, $-OR^4$, $-N(R^4)R^4$, C_{1-6} alkyl, heterocyclyl, heterocyclyl C_{1-6} alkyl, and a six-or sevenmembered heteroalicyclic formed by two adjacent of R^6 , together with the annular atoms to which they are attached, said six- or seven-membered heteroalicyclic containing up to two heteroatoms; or a pharmaceutically acceptable salt or stereoisomer, thereof.
- 45. (new) The compound according to claim 44, wherein at least one of R⁶ is -OR⁴ and R⁴ is C₁₋₆ alkyl optionally substituted with 1, 2, or 3 halogen; C₁₋₆ alkyl optionally substituted with alkoxy; C₁₋₆ alkyl substituted with amino where the amino is optionally substituted with one or groups selected from methyl, ethyl, -CH₂CH₂OCH₃, -CH₂CH₂N(CH₃)₂, -CH₂CH₂N(CH₃)₂, and *N*-methyl-pyrrolidin3-yl; and heterocyclyl where the heterocyclyl is optionally substituted with alkyl, acyl, NH₂, alkylamino, dialkylamino, heterocyclyl, cyclohexyl, -CH₂OCH₃, -CH₂C(O)NHCH(CH₃)₂, or -CH₂OCH₃; or a pharmaceutically acceptable salt or stereoisomer, thereof.
- 46. (new) The compound according to claim 45, wherein at least one of R¹ is halo or methyl; or a pharmaceutically acceptable salt or stereoisomer, thereof.
- 47. (new) The compound according to claim 46, wherein R^9 is selected from -H, trihalomethyl, and C_{1-6} alkyl optionally substituted with one group selected from alkoxy, benzylamino, and 2-oxo-pyrrolidinyl; or a pharmaceutically acceptable salt or stereoisomer, thereof.

Attorney Docket No.: EX04-017C-US Page 14 of 56
USSN: 10/565,657 Express Mail Tracking Number: EV 938 354 435 US

48. (new) The compound according to claim 44, wherein at least one of R^6 is $-OR^4$ and R^4 is heterocyclyl C_{1-6} alkyl where the heterocyclyl is a heteroalicyclic; or a pharmaceutically acceptable salt or stereoisomer, thereof.

The compound according to claim 48, wherein said heteroalicyclic is 49. (new) selected from the group consisting of dioxolanyl, piperidinyl, piperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, 2-oxopiperazinyl, azepinyl, 4-piperidonyl, pyrrolidinyl, morpholinyl, quinuclidinyl, tetrahydrofuryl, tetrahydropyranyl, thiamorpholinyl, thiamorpholinyl sulfoxide, 2,5-diazabicyclo[2.2.1]heptanyl, and thiamorpholinyl sulfone; or a pharmaceutically acceptable salt or stereoisomer, thereof.

50. (new) The compound according to claim 44, wherein at least one of R⁶ is -OR⁴ and R⁴ is alkyl substituted with at least one additional of alkoxyl, amino, dialkylamino, and monoalkylamino where the monoalkylamino is further sbustittued with *N*-methyl-pyrrolidin3-yl and where each alkyl of monoalkylamino and dialkylamino are independently optionally substituted with -NH₂, -NHCH₃, or -N(CH-)₂; or a pharmaceutically acceptable salt or stereoisomer, thereof.

51. (new) The compound according to claim 31, selected from Table 3; or a pharmaceutically acceptable salt or stereoisomer, thereof

Table 3

Entry	Name	Structure
10	4-{7,8-bis(methyloxy)-1-[(4-methylphenyl)methyl]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	HO—N=N-N

Table 3

Entry	Name	Structure
12	4-(7,8-bis(methyloxy)-1-{[4-(methyloxy)phenyl]methyl}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	HO N=N-N
13	4-{7,8-bis(methyloxy)-1-[(2-methylphenyl)methyl]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	N = N - N - N - N - N - N - N - N - N -
.14	4-{7,8-bis(methyloxy)-1-[(3-methylphenyl)methyl]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	HO N N N N
15	4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	N = N
20	4-[1-{[3,4-bis(methyloxy)phenyl]methyl}-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO \sim

Entry	Name	Structure
21	4-(7,8-bis(methyloxy)-1-{[3-(methyloxy)phenyl]methyl}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	HO N N N N
22	4-[1-ethyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N
25	4-[1-methyl-6,7,8- tris(methyloxy)-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl]phenol	HO N=NNN
27	4-[7,8-bis(methyloxy)-1- (trifluoromethyl)-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl]phenol	HO N=N N F
28	4-[1-(1-methylethyl)-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N

Table 3

Entry	Name	Structure
29	4-[7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	но — N N N N N N N N N N N N N N N N N N
31	4-[1-methyl-6,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N
32	4-[6,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N
34	4-[6,7,8-tris(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N
35	4-[1-methyl-7,8,9- tris(methyloxy)-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl]phenol	HO N N N N N N N N N N N N N N N N N N N

Table 3

Entry	Name	Structure
36	4-[1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N
37	2-methyl-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
38	4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-(methyloxy)phenol	O O O O O O O O O O
39	4-{1-methyl-8-(methyloxy)-7- [(2-morpholin-4-ylethyl)oxy]- 3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin- 5-yl}phenol	HZ Z O O O O O O O O O O O O O O O O O O
40	2-(ethyloxy)-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N

Table 3

	<u> </u>	able 3
Entry	Name	Structure
41	2-chloro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
42	2-fluoro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	F N N N N N N N N N N N N N N N N N N N
44	2-bromo-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	Br N N N N N N N N N N N N N N N N N N N
45	1-{[5-(4-hydroxyphenyl)-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-1-yl]methyl}pyrrolidin-2-one	HO N N N
54	4-{1-methyl-7-(methyloxy)-8- [(piperidin-4-ylmethyl)oxy]- 3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin- 5-yl}phenol	HN N NH

Table 3

Entry	Name	Structure
55	4-{1-methyl-8-(methyloxy)-7- [(piperidin-4-ylmethyl)oxy]- 3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin- 5-yl}phenol	OH OH NH
58	4-[8-(ethyloxy)-1-methyl-7- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N H
59	4-[1-methyl-8,9-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	DH CHANGE OF THE
60	4-[7-(ethyloxy)-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N H
61	4-{1-methyl-8-(methyloxy)-9- [(piperidin-4-ylmethyl)oxy]- 3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin- 5-yl}phenol	HO N N N N N N N N N N N N N N N N N N N

Table 3

Entry	Name	Structure
63	2-ethyl-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
64	4-(1-methyl-8-(methyloxy)-9- {[(1-methylpiperidin-4- yl)methyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	HO O N N N N N N N N N N N N N N N N N N
65	4-(1-methyl-7-(methyloxy)-8- {[(1-methylpiperidin-4- yl)methyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	-N, NH
66	4-[1,7-dimethyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
67	1,1-dimethylethyl 4-[5-(4-hydroxyphenyl)-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-1-yl]piperidine-1-carboxylate	HO NO

Table 3

Entry	Name	Structure
69	2-chloro-4-[1-methyl-8,9-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	CI N N N N N N N N N N N N N N N N N N N
70	2-fluoro-4-[1-methyl-8,9-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N=N-N
71	2-methyl-4-[1-methyl-8,9-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N=N-N
72	2-bromo-4-[1-methyl-8,9-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	Br N N N N N N N N N N N N N N N N N N N
76	2-[(difluoromethyl)oxy]-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	FO O O O O O O O O O O O O O O O O O O

Table 3

E 4		Stauratura
Entry	Name	Structure
78	4-[1,9-dimethyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
79	4-[6,9-difluoro-1-methyl-8- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
80	2-bromo-4-{1-methyl-8- (methyloxy)-9-[(2-morpholin- 4-ylethyl)oxy]-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl}phenol	N-NH NH N
81	2-chloro-4-{1-methyl-8- (methyloxy)-9-[(2-morpholin- 4-ylethyl)oxy]-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl}phenol	N-NH N-NH O-NH O-NH O-NH O-NH O-NH O-NH
82	4-(7,8-bis(methyloxy)-1- {[(phenylmethyl)amino]methyl} }-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	N = N + N + N + N + N + N + N + N + N +

Table 3

Entry	Name	Structure
83	2,5-dimethyl-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N
85	2,5-dichloro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	CI N N N N N N N N N N N N N N N N N N N
87	2-bromo-4-(1-methyl-8- (methyloxy)-9-{[(1- methylpiperidin-4- yl)methyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	HO Br O N N N N N N N N N N N N N N N N N N
88	2-chloro-4-(1-methyl-7- (methyloxy)-8-{[(1- methylpiperidin-4- yl)methyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	H Z O O O O O
89	4-[9-fluoro-1-methyl-8- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- c]isoquinolin-5-yl]phenol	HO — N N N N N N N N N N N N N N N N N N

Page 25 of 56 Express Mail Tracking Number: EV 938 354 435 US

Attorney Docket No.: EX04-017C-US USSN: 10/565,657

Table 3

Entry	Name	Structure
90	4-(1-methyl-8-(methyloxy)-9- {[2-(methyloxy)ethyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	N-NH NOH
91	2-chloro-4-(1-methyl-8- (methyloxy)-9-{[(1- methylpiperidin-4- yl)methyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	HO CI O N N N N N N N N N N N N N N N N N N
92	4-[6-bromo-1,7-dimethyl-8- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N
93	4-[6-fluoro-1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N H
94	4-[9-chloro-1,7-dimethyl-8- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO CI

		able 5
Entry	Name	Structure
95	2-chloro-4-[8-{[(1-ethylpiperidin-4-yl)methyl]oxy}-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	DH Z OH CO
96	3-chloro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO CI NEW
97	4-(1-methyl-8,9-bis{[2- (methyloxy)ethyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	HO N N N N N N N N N N N N N N N N N N N
98	4-(1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	HO N=N-N
99	2-chloro-4-(1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	HO N N N

Entry	Name	Structure
100	2-bromo-4-(1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	HO N N N N N N N N N N N N N N N N N N N
101	2-chloro-4-[1,7-dimethyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
102	2-bromo-4-[1,7-dimethyl-8- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	Br N-N H
103	2-chloro-4-[1-methyl-8-({[1-(1-methylethyl)piperidin-4-yl]methyl}oxy)-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	NH NH CI
104	4-[9-bromo-1-methyl-8- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N

Table 3

Entry	Name	Structure
105	4-[7-chloro-9-fluoro-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
106	4-[8-{[(1-acetylpiperidin-4-yl)methyl]oxy}-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4-c]isoquinolin-5-yl]-2-chlorophenol	H N OH CI
107	4-[9-{[(1-acetylpiperidin-4-yl)methyl]oxy}-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4-c]isoquinolin-5-yl]-2-bromophenol	HO N N N N N N N N N N N N N N N N N N N
108	2-chloro-4-(1-methyl-9- (methyloxy)-8-{[2- (methyloxy)ethyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	OH CI
109	4-[7-fluoro-1-methyl-8- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N H

Table 3

Entry	Name	Structure
110	2-chloro-4-(1-methyl-8,9-bis{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
111	2-bromo-4-(1-methyl-8,9-bis{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	Br O O O O O O O O O O O O O O O O O O O
112	2-chloro-4-(1-methyl-8- (methyloxy)-9-{[2- (methyloxy)ethyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	N-NH N-OH CI
113	2-bromo-4-(1-methyl-8- (methyloxy)-9-{[2- (methyloxy)ethyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	N-NH N O O O O Br

Table 3

Entry	Name	Structure
114	3-fluoro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N H
115	2-chloro-4-(1-methyl-7- (methyloxy)-8-{[2- (methyloxy)ethyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	CI HO N= N-N H
116	2-bromo-4-(1-methyl-7- (methyloxy)-8-{[2- (methyloxy)ethyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	Br N N N N N N N N N N N N N N N N N N N
117	2-chloro-4-(1-methyl-7,8-bis{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
118	2-bromo-4-(1-methyl-7,8-bis{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	Br N N N H

Table 3

		able 3
Entry	Name	Structure
120	4-(6,9-difluoro-1-methyl-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	OH HN N
121	2-chloro-5-fluoro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
122	2-bromo-5-fluoro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	Br N N N H
123	4-[9-fluoro-1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -benzo[e]indazol-5-yl]phenol	O O O O O O O O O O O O O O O O O O O
125	3-fluoro-4-(1-methyl-7- (methyloxy)-8-{[2- (methyloxy)ethyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	E Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z

Table 3

Entry	Name	Structure
126	4-(6,9-difluoro-1-methyl-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)-3-fluorophenol	OH F N HN, N
127	2-chloro-4-(6,9-difluoro-1- methyl-8-{[2- (methyloxy)ethyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	CI F F O F
128	2-chloro-4-[8-(ethyloxy)-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	CI N N N N N N N N N N N N N N N N N N N
129	2-chloro-4-[6-chloro-1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	H OH
130	3-fluoro-4-(1-methyl-9- (methyloxy)-8-{[2- (methyloxy)ethyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	OH F N N O

Table 3		
Entry	Name	Structure
131	2-chloro-4-(1,7-dimethyl-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	HO N N N N N N N N N N N N N N N N N N N
132	3-fluoro-4-(6-fluoro-1-methyl-7-(methyloxy)-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	OH F N N
133	2-chloro-4-[1-methyl-8-[(1-methylethyl)oxy]-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N
134	2-chloro-4-{1-methyl-7- (methyloxy)-8-[(2- methylpropyl)oxy]-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl}phenol	N-NH N-NH O O O O O O O
135	2-bromo-5-fluoro-4-(1-methyl-7-(methyloxy)-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	N N F OH

Attorney Docket No.: EX04-017C-US
USSN: 10/565,657
Page 34 of 56
Express Mail Tracking Number: EV 938 354 435 US

Table 3

Enton	Name	Structure
Entry 136	4-[7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	H OH CI
137	4-[7,8-bis(methyloxy)-1- (trifluoromethyl)-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl]-2-chlorophenol	CI HO N= N= N= N= N= N= N= N= N= N= N= N= N=
138	4-{7,8-bis(methyloxy)-1- [(methyloxy)methyl]-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl}-2-chlorophenol	CI N N N N H
139	2-chloro-4-(1-methyl-3 <i>H</i> - [1,3]dioxolo[4,5- g]pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	CI N N N H
140	2-chloro-4-(1-methyl-8,9-dihydro-3 <i>H</i> -[1,4]dioxino[2,3-g]pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	CI N N N H

Entry	Name	Structure
141	2-chloro-4-(1-methyl-9,10-dihydro-3 <i>H</i> ,8 <i>H</i> -[1,4]dioxepino[2,3-g]pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	CI N N N N N N N N N N N N N N N N N N N
142	2-chloro-4-[7- [(difluoromethyl)oxy]-1- methyl-8-(methyloxy)-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl]phenol	F F O O O O O O O O O O O O O O O O O O
143	2-chloro-5-fluoro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	N-NH N-NH O
144	2-chloro-4-(6,9-difluoro-1-methyl-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)-5-fluorophenol	HO F N H
145	2-chloro-4-(11-methyl-2,3-dihydro-9 <i>H</i> -[1,4]dioxino[2,3-f]pyrazolo[3,4- <i>c</i>]isoquinolin-7-yl)phenol	CI N N N N N N N N N N N N N N N N N N N

Page 36 of 56 Express Mail Tracking Number: EV 938 354 435 US

Attorney Docket No.: EX04-017C-US USSN: 10/565,657

Table 3

Entry	Name	Structure
146	2-chloro-5-fluoro-4-(11-methyl-2,3-dihydro-9 <i>H</i> -[1,4]dioxino[2,3-f]pyrazolo[3,4- <i>c</i>]isoquinolin-7-yl)phenol	N-NH N-NH N-NH N-NH N-OH CI
147	2-chloro-4-[1-methyl-6,7,8- tris(methyloxy)-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl]phenol	CI O N N N N N N N N N N N N N N N N N N
148	2-bromo-4-(6,9-difluoro-1- methyl-8-{[2- (methyloxy)ethyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)-5-fluorophenol	Br F N N N H
149	7-(3-chlorophenyl)-11-methyl- 2,3-dihydro-9 <i>H</i> - [1,4]dioxino[2,3- f]pyrazolo[3,4- <i>c</i>]isoquinoline	N-NH NCI
150	2-chloro-5-fluoro-4-(6-fluoro- 1-methyl-8,9-dihydro-3 <i>H</i> - [1,4]dioxino[2,3- g]pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	CI F N N N H

Table 3

Entry	Name	Structure
151	2-chloro-4-{1-methyl-7- (methyloxy)-8- [(tetrahydrofuran-2- ylmethyl)oxy]-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl}phenol	N-NH N O O O CI
152	2-chloro-4-{1-methyl-7- (methyloxy)-8-[(tetrahydro-2 <i>H</i> - pyran-2-ylmethyl)oxy]-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl}phenol	N-NH N-NH CI
153	2-chloro-4-{1-methyl-7- (methyloxy)-8-[(2,2,2- trifluoroethyl)oxy]-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl}phenol	F F O O O O
154	2-chloro-5-fluoro-4-[9-fluoro-1-methyl-6,7,8-tris(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	CI O F HO N N N N N N N N N N N N N N N N N N N
155	5-(3-chloro-4-hydroxyphenyl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	N-NH N F HO F OH

Table 3

	Table 5		
Entry	Name	Structure	
156	6,9-difluoro-5-(2-fluorophenyl)-1-methyl-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinoline	F N NH	
157	2-chloro-4-{8- [(difluoromethyl)oxy]-6,9- difluoro-1-methyl-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl}phenol	F O F OH	
158	2-chloro-4-(6,11-difluoro-1-methyl-8,9-dihydro-3 <i>H</i> -[1,4]dioxino[2,3-g]pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)-5-fluorophenol	CI F F F N N N N H	
159	4-(1-methyl-3 <i>H</i> -benzo[e]indazol-5-yl)phenol	N N N N N N N N N N N N N N N N N N N	
160	6-fluoro-7-(2-fluorophenyl)-11- methyl-2,3-dihydro-9 <i>H</i> - [1,4]dioxino[2,3- f]pyrazolo[3,4- <i>c</i>]isoquinoline	N-NH N F	
161	2-chloro-4-{1-methyl-7- (methyloxy)-8-[(tetrahydro-2 <i>H</i> - pyran-4-ylmethyl)oxy]-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl}phenol	N-NH N-NH O	

<u> </u>		able 5
Entry	Name	Structure
162	2-chloro-4-[8-{[2- (ethyloxy)ethyl]oxy}-1-methyl- 7-(methyloxy)-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl]phenol	CI N N N N N N N N N N N N N N N N N N N
164	3-fluoro-4-(6-fluoro-11-methyl- 2,3-dihydro-9 <i>H</i> - [1,4]dioxino[2,3- f]pyrazolo[3,4- <i>c</i>]isoquinolin-7- yl)phenol	N-NH N F OH
165	2-chloro-5-fluoro-4-(6-fluoro- 11-methyl-2,3-dihydro-9 <i>H</i> - [1,4]dioxino[2,3- f]pyrazolo[3,4- <i>c</i>]isoquinolin-7- yl)phenol	N-NH N F OH CI
166	2-chloro-4-[8-(cyclopentyloxy)-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	N-NH N-OH CI
167	2-chloro-4-(1-methyl-7-(1-methylethyl)-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	HO N N N

Table 3

E-4	<u> </u>	Standards
Entry	Name	Structure
168	2-chloro-4-[9-ethyl-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
169	2-chloro-4-(6,9-difluoro-1-methyl-8-{[(1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	N-NH N-NH OH CI
170	5-(3-chloro-4-hydroxyphenyl)- 8-fluoro-1-methyl-7- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-6-ol	HO HO N N N N
171	2-chloro-4-(6-fluoro-1-methyl-7-(methyloxy)-8-{[(1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	N-NH N O F CI
172	2-chloro-4-(6-fluoro-1-methyl- 8,9-bis{[2- (methyloxy)ethyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	

		able 3
Entry	Name	Structure
173	5-[3-chloro-4- (methyloxy)phenyl]-6-fluoro-1- methyl-7-(methyloxy)-8-{[(1- methylpiperidin-4- yl)methyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinoline	N, NH N CI O O
174	5-[3-chloro-4- (methyloxy)phenyl]-8-fluoro-1- methyl-7-(methyloxy)-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-6-ol	HO N N N N N N N N N N N N N N N N N N N
176	2-chloro-4-{6-fluoro-1-methyl-7-(methyloxy)-8-[(2-piperidin-1-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	H Z OH
177	2-chloro-4-[8-{[2-(4-ethylpiperazin-1-yl)ethyl]oxy}-6-fluoro-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	H Z OH OH
178	2-chloro-4-[8-{[2- (diethylamino)ethyl]oxy}-6- fluoro-1-methyl-7-(methyloxy)- 3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin- 5-yl]phenol	H Z O O O O

Attorney Docket No.: EX04-017C-US USSN: 10/565,657

Table 3

Entry	Name	Structure
179	2-chloro-4-(6-fluoro-1-methyl-7-(methyloxy)-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	CI F O O O O O O O O O O O O O O O O O O
182	2-chloro-4-(6-fluoro-1-methyl- 9-(methyloxy)-8-{[(1- methylpiperidin-4- yl)methyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	N-NH N-NH N-NH CI
183	2-bromo-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{[(1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	H Z O O Br
184	2-chloro-5-fluoro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{[(1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	N F OH CI
185	4-(6-fluoro-1-methyl-9- (methyloxy)-8-{[(1- methylpiperidin-4- yl)methyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)-2-methylphenol	N-NH N-NH N-NH N-NH N-NH N-NH N-NH N-NH

Table 3

Entry	Name	Structure
186	2-chloro-4-{6,9-difluoro-1-methyl-8-[(2-piperidin-1-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	P C OH
187	2-chloro-4-(8-{[2-(4-ethylpiperazin-1-yl)ethyl]oxy}-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
188	2-chloro-4-(8-{[2- (diethylamino)ethyl]oxy}-6,9- difluoro-1-methyl-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	P
191	6,9-difluoro-5-(1 <i>H</i> -indol-5-yl)- 1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	F F N N N H
193	5-(4-aminophenyl)-6,9- difluoro-1-methyl-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	$F \longrightarrow F$ $H_2N \longrightarrow N$ $N \longrightarrow N$ H

Entry	Name	Structure
194	2-chloro-4-(6-fluoro-1-methyl-7-(methyloxy)-8-{[2-(4-methylpiperazin-1-yl)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4-c]isoquinolin-5-yl)phenol	N-NH N-NH N-NH OFFOH
195	5-(2-amino-1,3-thiazol-5-yl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	N-NH N N N N N N N N N N N N N N N N N
196	2-chloro-4-[8-{[2-(4-ethylpiperazin-1-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	OH CI PL Z
197	2-chloro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{[2-(4-methylpiperazin-1-yl)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	NH NH OH CI
198	5-(6-aminopyridin-3-yl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	H_2N N N N N N N N N N

Table 3

Entry	Name	Structure
199	5-(5-amino-2-thienyl)-6,9- difluoro-1-methyl-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	H ₂ N S N N N N N N N N N N N N N N N N N N
200	2-chloro-4-[8-{[3-(4-ethylpiperazin-1-yl)propyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	N NH O F CI OH
201	2-chloro-4-(6-fluoro-1-methyl- 9-(methyloxy)-8-{[3-(4- methylpiperazin-1- yl)propyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	-N N CI OH
202	6,9-difluoro-5-(1 <i>H</i> -indol-6-yl)- 1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	N-NH F HN HO F
203	N-[5-(6,9-difluoro-8-hydroxy-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)-1,3-thiazol-2-yl]acetamide	F F N N N N N N N N N N N N N N N N N N

Table 3

Entry	Name	Structure
206	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(2-morpholin-4-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	N-NH N-NH N-NH N-NH CI
207	4-[8-({2- [butyl(ethyl)amino]ethyl}oxy)- 6-fluoro-1-methyl-9- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2- chlorophenol	N-NH N-NH N-NH N-NH N-NH N-NH N-NH N-NH
208	4-[8-{[(2R)-2-amino-3-methylbutyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	N-NH N O F O O F O O O O O O O O O O O O O O
209	2-chloro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{[2-(1-methylpiperidin-4-yl)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	N-NH N-NH N-NH N-NH N-NH N-NH N-NH N-NH
210	2-chloro-4-[8-{[(1-ethylpiperidin-4-yl)methyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	N-NH N-NH N-NH OH CI

Table 3

		SAA
Entry	Name	Structure
212	5-(5-amino-1,3,4-thiadiazol-2-yl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	F HO S NH ₂
213	4-[8-{[(2 <i>R</i>)-2-amino-3,3-dimethylbutyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	CI F O NH2
214	2-chloro-4-[6-fluoro-1-methyl-9-(methyloxy)-8-({2-[4-(2-methylpropyl)piperazin-1-yl]ethyl}oxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	OH CI F N N N
215	2-chloro-4-[8-{[2-(5-ethyl-2,5-diazabicyclo[2.2.1]hept-2-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyṛazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	N-NH N O F O O CI
216	2-chloro-4-[6-fluoro-1-methyl-8-({2-[4-(1-methylethyl)piperazin-1-yl]ethyl}oxy)-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	OH CI P N N N N N N N N N N N N N N N N N N

		able 3
Entry	Name	Structure
217	4-[8-{[2-(3-amino-8-azabicyclo[3.2.1]oct-8-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	H ₂ N O H
218	2-chloro-4-[8-{[2-(1-ethylpiperidin-4-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	OH CI F N N N N N N N N N N N N N N N N N N
219	2-chloro-4-[8-{[2- (diethylamino)ethyl]oxy}-6- fluoro-1-methyl-9-(methyloxy)- 3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin- 5-yl]phenol	N O O O O O O O O O O O O O O O O O O O
220	2-chloro-5-{6-fluoro-1-methyl-9-(methyloxy)-8-[(2-pyrrolidin-1-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	N NH N OH CI
223	2-chloro-4-[6-fluoro-1-methyl-8-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)oxy]-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	OH CI P N N N N N N N N N N N N N N N N N N

_	_	able 5
Entry	Name	Structure
224	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(3-pyrrolidin-1-ylpropyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	N-NH O F OH
225	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(3-piperidin-1-ylpropyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	N-NH O F CI
226	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(3-morpholin-4-ylpropyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	N-NH N-NH N-NH N-OH CI
227	2-chloro-4-[8-({2-[[2-(dimethylamino)ethyl](methyl) amino]ethyl}oxy)-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	N-NH N-NH N-NH N-NH N-NH N-NH N-NH N-NH
228	2-chloro-4-[8-({2-[[2-(diethylamino)ethyl](methyl)a mino]ethyl}oxy)-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	OH CI P P P P P P P P P P P P P P P P P P

Table 3

Entry	Name	Structure
229	2-chloro-4-[8-({2-[[2-(dimethylamino)ethyl](ethyl)a mino]ethyl}oxy)-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	OH CI
230	4-[8-[(2-{bis[3- (dimethylamino)propyl]amino} ethyl)oxy]-6-fluoro-1-methyl-9- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2- chlorophenol	OH CI N N N N N N N N N N N N N N N N N N
231	2-chloro-4-[6-fluoro-1-methyl-8-({2-[methyl(1-methylpyrrolidin-3-yl)amino]ethyl}oxy)-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	N-NH N O F O H CI
232	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(2-{(2S)-2-[(methyloxy)methyl]pyrrolidin-1-yl}ethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	HO F O N O N O N O N O N O N O N O N O N
233	2-chloro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{[2-(4-pyrrolidin-1-ylpiperidin-1-yl)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	N-NH NOFFOH

Entry	Name	Structure
234	2-chloro-4-[8-{[2-(4-cyclohexylpiperazin-1-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	N-NH N-NH N-NH N-OH CI
235	2-[4-(2-{[5-(3-chloro-4-hydroxyphenyl)-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-yl]oxy}ethyl)piperazin-1-yl]- <i>N</i> -(1-methylethyl)acetamide	
236	4-[8-{[2-(1,4'-bipiperidin-1'-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	$\begin{array}{c c} & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ &$
237	2-chloro-4-[6-fluoro-1-methyl-8-{[2-(4-methyl-1,4-diazepan-1-yl)ethyl]oxy}-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
238	2-chloro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{[2-(4-pyridin-2-ylpiperazin-1-yl)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	NH N

Table 3

Entry	Name	Structure
239	2-chloro-4-[8-{[2-(2,6-dimethylmorpholin-4-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
240	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(2-thiomorpholin-4-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	N-NH N O F O O F O O O O O O O
241	2-chloro-4-[8-{[2-(2,6-dimethylpiperidin-1-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	N-NH N-NH OH CI
242	2-chloro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{[2-(octahydroquinolin-1(2 <i>H</i>)-yl)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	N-NH N-NH N-OH CI
243	4-[8-({2-[bis(1-methylethyl)amino]ethyl}oxy)-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	N-NH N-NH N-NH OH CI

Page 53 of 56 Express Mail Tracking Number: EV 938 354 435 US

Attorney Docket No.: EX04-017C-US USSN: 10/565,657

Table 3

Entry	Name	Structure
244	4-[8-[(2-{bis[2- (methyloxy)ethyl]amino}ethyl) oxy]-6-fluoro-1-methyl-9- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2- chlorophenol	OH CI
245	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(2-piperidin-1-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	N-NH N O F CI

A Compound selected from 52. (new)

9	4-[7,8-bis(methyloxy)-1- (phenylmethyl)-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl]benzene-1,2-diol	HO N N N N N
19	4-[7,8-bis(methyloxy)-1-(1-phenylethyl)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	OOO OOO OOO OOO OOO OOO OOO OOO

Page 54 of 56 Express Mail Tracking Number: EV 938 354 435 US

Attorney Docket No.: EX04-017C-US USSN: 10/565,657

24	4-[6,7,8-tris(methyloxy)-1- (phenylmethyl)-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl]phenol	N = N = N = N = N = N = N = N = N = N =
26	4-[8-(methyloxy)-1- (phenylmethyl)-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl]phenol	HO N=N-N
221	6,9-difluoro-5-(2-imino-3-methyl-2,3-dihydro-1,3-thiazol-5-yl)-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	H S NH F HO

- 53. (new) A pharmaceutical composition comprising the compound according to claim 31 and a pharmaceutically acceptable carrier.
- 54. (new) A method of modulating the *in vivo* activity of a kinase, the method comprising administering to a subject an effective amount of the compound or the pharmaceutical composition according to claim 31.
- 55. (new) The method according to claim 54, wherein the kinase is ALK.
- 56. (new) The method according to claim 55, wherein modulating the *in vivo* activity of ALK comprises inhibition of ALK.
- 57. (new) A method of treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a

Attorney Docket No.: EX04-017C-US Page 55 of 56 Express Mail Tracking Number: EV 938 354 435 US

USSN: 10/565,657

mammal in need thereof, a therapeutically effective amount of the compound or the pharmaceutical composition as described in any one of claims 31.

The method of claim 57 where the disease is an ALK-positive lymphomas, 58. (new) B-cell lymphoma, neuroblastoma, or inflammatory myofibroblastic tumors.